Description
The goal of this research is to see if Intestinal Ultrasound (IUS) improvement at week 4 can be used to predict long-term remission (a decrease or disappearance of symptoms) at 1 year following treatment with mirikizumab-mrkz. Mirikizumab-mrkz is FDA approved to treat UC. The study is considered investigational because we are using IUS after starting therapy with Mirikizumab-mrkz which has not been done before. We are evaluating early ultrasound changes after starting therapy. The study may help researchers assess early for response to mirikizumab-mrkz by using the IUS and compare it to findings on a colonoscopy, but this cannot be promised. Future patients may benefit from what is learned.
